According to preliminary research, co-treatment with Src inhibitors such as dasatinib may re-sensitize colorectal cancers resistant to conventional platinum-based chemotherapeutic drugs, such as oxaliplatin [38]. This evidence concerns the gene SRC and colorectal cancer.